<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006178</url>
  </required_header>
  <id_info>
    <org_study_id>000196</org_study_id>
    <secondary_id>00-DK-0196</secondary_id>
    <nct_id>NCT00006178</nct_id>
  </id_info>
  <brief_title>Sirolimus and Thymoglobulin to Prevent Kidney Transplant Rejection</brief_title>
  <official_title>Sirolimus Monotherapy to Optimize Activation Induced Cell Death (AICD) in Renal Transplants Following Lymphocyte Depletion Induction With Thymoglobulin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      This study will test the safety and effectiveness of two drugs, Sirolimus and Thymoglobulin,&#xD;
      for preventing rejection of transplanted kidneys. Standard anti-rejection therapy uses a&#xD;
      combination of drugs, such as cyclosporine, tacrolimus, azathioprine, steroids, and others,&#xD;
      that are taken daily for life. However, even with this daily therapy, more than half of&#xD;
      kidney recipients slowly reject their transplant within 10 years. Both Thymoglobulin, an&#xD;
      antibody, and Sirolimus, an anti-rejection drug, prevent rejection by lowering the response&#xD;
      of the immune system to the transplanted organ. Thymoglobulin is given in the pre- and&#xD;
      postoperative period, and Sirolimus is taken long term.&#xD;
&#xD;
      Patients who receive a kidney transplant at the National Institutes of Health Clinical Center&#xD;
      are eligible for this study. Candidates will be screened with a medical history, physical&#xD;
      examination, and blood and urine tests.&#xD;
&#xD;
      Participants will undergo a kidney transplant. Before the surgery, a central line&#xD;
      (intravenous catheter), through which blood and medicine can be given, is placed in the neck&#xD;
      or chest. Patients may also undergo leukapheresis, a procedure for collecting white blood&#xD;
      cells. The cells can be stored for transfusion later if white cell counts drop following&#xD;
      Thymoglobulin treatment. For this procedure, blood is drawn from a needle placed in the arm&#xD;
      and flows into a machine that separates the blood components by spinning. The white cells are&#xD;
      collected in a bag and the red cells and plasma are returned through a second needle in the&#xD;
      other arm.&#xD;
&#xD;
      Thymoglobulin will be given intravenously the day before the transplant and days 1 through 9&#xD;
      after the operation. Sirolimus will be taken by mouth, mixed with water or orange juice.&#xD;
      Sirolimus therapy starts the day of the transplant and continues for life.&#xD;
&#xD;
      Follow-up study visits will be scheduled weekly for the first month after the transplant,&#xD;
      then every 6 months for 1 year and then once a year for 4 years. Procedures during these&#xD;
      visits may include blood and urine tests, physical examination, and check of vital signs&#xD;
      (i.e., blood pressure, heart rate, breathing rate, temperature). Kidney biopsies (removal of&#xD;
      a small piece of tissue for examination under the microscope) will be done at 2 weeks, 1&#xD;
      month and 6 months after surgery and then yearly for 4 years to check for any damage to the&#xD;
      kidney. In addition, a local doctor will do routine laboratory tests 2 to 3 times a week for&#xD;
      the first 2 to 3 months aft...&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol will test a novel dual agent combination therapy for its ability to prevent&#xD;
      human renal allograft rejection. Thymoglobulin (Sangstat), a FDA-approved polyclonal&#xD;
      rabbit-IgG antithymocyte preparation, will be given for ten days at the time of&#xD;
      transplantation to achieve profound lymphocyte depletion. This will be paired with chronic&#xD;
      therapy with Sirolimus (rapamycin, Wyeth-Ayerst), an oral immunosuppressant agent recently&#xD;
      approved by the FDA. Rapamycin allows for antigen specific T cell activation but prevents T&#xD;
      cell clonal expansion by interrupting IL-2 receptor beta-chain signal transduction. The&#xD;
      rationale for this combination is to eliminate existing alloreactive T cell clones that could&#xD;
      initiate a rejection at the time of transplantation, and to promote graft specific activation&#xD;
      induced cell death (AICD) in repopulating T cells such that an allospecific T cell deficit is&#xD;
      induced. The desired effect of this therapy is to prevent allograft rejection without the&#xD;
      chronic use of calcineurin inhibitors or glucocorticosteroids, and in doing so, develop a&#xD;
      regimen for transplantation that avoids most of the chronic drug toxicities inherent in the&#xD;
      use of these two classes of immunosuppressants.&#xD;
&#xD;
      Twenty people will be evaluated in this pilot protocol. Ten will receive living donor kidney&#xD;
      allografts and ten will receive cadaveric kidney allografts. Patients will be treated with&#xD;
      Thymoglobulin beginning prior to graft implantation and continuing for ten days.&#xD;
      Glucocorticosteroids will be given during the Thymoglobulin treatment to limit monocyte&#xD;
      activation and prevent the cytokine release syndrome associated with this antibody&#xD;
      preparation. Patients will be given Sirolimus orally beginning the day after transplantation&#xD;
      and continuously thereafter. Patients will then be monitored for evidence of allograft&#xD;
      rejection using standard functional parameters and protocol allograft biopsies. In addition,&#xD;
      patients will be followed for a specific desired effect, allospecific AICD, that should&#xD;
      promote the development of allospecific graft tolerance. This will be accomplished by&#xD;
      assaying peripheral blood and allograft biopsies for apoptosis and peripheral blood for&#xD;
      evidence of alloreactive T cell clone depletion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2000</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Creatinine Concentration</measure>
    <time_frame>6 months after intervention</time_frame>
    <description>measures at 6 months after intervention</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum Creatinine Concentration</measure>
    <time_frame>12 months after intervention</time_frame>
    <description>measures at 12 months after intervention</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glomerular Filtration Rate (Flow Rate of Filtered Fluid Through the Kidney)</measure>
    <time_frame>6 month after intervention</time_frame>
    <description>measure 6 months after intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glomerular Filtration Rate (Flow Rate of Filtered Fluid Through the Kidney)</measure>
    <time_frame>12 months after intervention</time_frame>
    <description>measure at 12 months after intervention</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Kidney Failure</condition>
  <arm_group>
    <arm_group_label>Sirolimus and Thymoglobulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Thymoglobulin (Sangstat), a FDA-approved polyclonal rabbit-IgG antithymocyte preparation, will be given for ten days at the time of transplantation to achieve profound lymphocyte depletion. This will be paired with chronic therapy with Sirolimus (rapamycin, Wyeth-Ayerst), an oral immunosuppressant agent recently approved by the FDA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <arm_group_label>Sirolimus and Thymoglobulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <arm_group_label>Sirolimus and Thymoglobulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        Candidates for a kidney transplant performed at the NIH Clinical Center.&#xD;
&#xD;
        Willingness and legal ability to give informed consent.&#xD;
&#xD;
        Availability of donor tissue for testing. This could include splenic or peripheral blood&#xD;
        lymphocytes from a cadaveric donor or a willing living donor enrolled on the Clinical&#xD;
        Center Living Donor Protocol who consents to periodic phlebotomy for peripheral blood&#xD;
        lymphocyte isolation.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        Immunosuppressive drug therapy at the time of or 2 months prior to enrollment.&#xD;
        Specifically, candidates may not be taking prednisone, cyclosporine, tacrolimus,&#xD;
        azathioprine, mycophenolate mofetil, anti-lymphocyte agents, cyclophosphamide,&#xD;
        methotrexate, or other agents whose therapeutic effect is immunosuppressive.&#xD;
&#xD;
        Any active malignancy or any history of a hematogenous malignancy or lymphoma. Patients&#xD;
        with primary, cutaneous basal cell or squamous cell cancers may be enrolled providing the&#xD;
        lesions are appropriately treated prior to transplant.&#xD;
&#xD;
        Significant coagulopathy or requirement for anticoagulation therapy that would&#xD;
        contraindicate protocol allograft biopsies.&#xD;
&#xD;
        Platelet count less than 100,000/mm(3).&#xD;
&#xD;
        Any known immunodeficiency syndrome.&#xD;
&#xD;
        Any history of cardiac insufficiency, major vascular disease, symptomatic coronary artery&#xD;
        disease.&#xD;
&#xD;
        Systemic or pulmonary edema.&#xD;
&#xD;
        Inability to be effectively dialyzed.&#xD;
&#xD;
        Any condition that would likely increase the risk of protocol participation or confound the&#xD;
        interpretation of the data.&#xD;
&#xD;
        Any history of sensitization to rabbits or extensive exposure to rabbits.&#xD;
&#xD;
        Inability or unwillingness to comply with protocol monitoring and therapy, including, among&#xD;
        others, a history of noncompliance, circumstances where compliance with protocol&#xD;
        requirements is not feasible due to living conditions, travel restrictions, access to&#xD;
        urgent medical services, or access to anti-rejection drugs after the research protocol is&#xD;
        completed.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/detail/B_2000-DK-0196.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Matas AJ, Gillingham KJ, Sutherland DE. Half-life and risk factors for kidney transplant outcome--importance of death with function. Transplantation. 1993 Apr;55(4):757-61. doi: 10.1097/00007890-199304000-00014.</citation>
    <PMID>8475549</PMID>
  </reference>
  <reference>
    <citation>Morris PJ. Renal transplantation: a quarter century of achievement. Semin Nephrol. 1997 May;17(3):188-95.</citation>
    <PMID>9165648</PMID>
  </reference>
  <reference>
    <citation>Swanson SJ, Hale DA, Mannon RB, Kleiner DE, Cendales LC, Chamberlain CE, Polly SM, Harlan DM, Kirk AD. Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet. 2002 Nov 23;360(9346):1662-4. doi: 10.1016/S0140-6736(02)11606-0.</citation>
    <PMID>12457792</PMID>
  </reference>
  <verification_date>June 2010</verification_date>
  <study_first_submitted>August 15, 2000</study_first_submitted>
  <study_first_submitted_qc>August 15, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2000</study_first_posted>
  <results_first_submitted>January 14, 2010</results_first_submitted>
  <results_first_submitted_qc>January 15, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 11, 2010</results_first_posted>
  <last_update_submitted>September 9, 2019</last_update_submitted>
  <last_update_submitted_qc>September 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal Failure</keyword>
  <keyword>Anti-rejection</keyword>
  <keyword>Apoptosis</keyword>
  <keyword>Polyclonal Antibody</keyword>
  <keyword>Kidney Transplant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sirolimus and Thymoglobulin</title>
          <description>Thymoglobulin (Sangstat) will be given for ten days at the time of transplantation to achieve profound lymphocyte depletion. This will be paired with chronic therapy with Sirolimus (rapamycin, Wyeth-Ayerst)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sirolimus and Thymoglobulin</title>
          <description>Thymoglobulin (Sangstat) will be given for ten days at the time of transplantation to achieve profound lymphocyte depletion. This will be paired with chronic therapy with Sirolimus (rapamycin, Wyeth-Ayerst)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.0" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Glomerular Filtration Rate (Flow Rate of Filtered Fluid Through the Kidney)</title>
        <description>measure 6 months after intervention</description>
        <time_frame>6 month after intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus and Thymoglobulin</title>
            <description>Thymoglobulin (Sangstat) will be given for ten days at the time of transplantation to achieve profound lymphocyte depletion. This will be paired with chronic therapy with Sirolimus (rapamycin, Wyeth-Ayerst)</description>
          </group>
        </group_list>
        <measure>
          <title>Glomerular Filtration Rate (Flow Rate of Filtered Fluid Through the Kidney)</title>
          <description>measure 6 months after intervention</description>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.1" spread="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Creatinine Concentration</title>
        <description>measures at 6 months after intervention</description>
        <time_frame>6 months after intervention</time_frame>
        <population>Analysis includes all participants in the study. Analysis was per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus and Thymoglobulin</title>
            <description>Thymoglobulin (Sangstat) will be given for ten days at the time of transplantation to achieve profound lymphocyte depletion. This will be paired with chronic therapy with Sirolimus (rapamycin, Wyeth-Ayerst)</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Creatinine Concentration</title>
          <description>measures at 6 months after intervention</description>
          <population>Analysis includes all participants in the study. Analysis was per protocol.</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112" spread="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Serum Creatinine Concentration</title>
        <description>measures at 12 months after intervention</description>
        <time_frame>12 months after intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus and Thymoglobulin</title>
            <description>Thymoglobulin (Sangstat) will be given for ten days at the time of transplantation to achieve profound lymphocyte depletion. This will be paired with chronic therapy with Sirolimus (rapamycin, Wyeth-Ayerst)</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Creatinine Concentration</title>
          <description>measures at 12 months after intervention</description>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107" spread="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glomerular Filtration Rate (Flow Rate of Filtered Fluid Through the Kidney)</title>
        <description>measure at 12 months after intervention</description>
        <time_frame>12 months after intervention</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sirolimus and Thymoglobulin</title>
            <description>Thymoglobulin (Sangstat) will be given for ten days at the time of transplantation to achieve profound lymphocyte depletion. This will be paired with chronic therapy with Sirolimus (rapamycin, Wyeth-Ayerst)</description>
          </group>
        </group_list>
        <measure>
          <title>Glomerular Filtration Rate (Flow Rate of Filtered Fluid Through the Kidney)</title>
          <description>measure at 12 months after intervention</description>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.2" spread="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Sirolimus and Thymoglobulin</title>
          <description>Thymoglobulin (Sangstat) will be given for ten days at the time of transplantation to achieve profound lymphocyte depletion. This will be paired with chronic therapy with Sirolimus (rapamycin, Wyeth-Ayerst)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute cellular rejection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>varicella zoster reactivation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>postpolio motor neuropathy</sub_title>
                <description>postpolio motor neuropathy 1 year after transplantation responsive to intravenous immunoglobulin</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sirolimus-side-effect (diarrhoea)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sirolimus-side-effect (mouth ulcers)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sirolimus-side-effect (arthralgias)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sirolimus-side-effect (hyperlipidaemia)</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>lymphocoele</sub_title>
                <description>lymphocoele needing transperitoneal drainage</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>diabetic foot cellulitis</sub_title>
                <description>diabetic foot cellulitis 15 months after transplantation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>bacterial urnary tract infection</sub_title>
                <description>bacterial urinary tract infection with infected polycystic kidneys and a pretransplantation neurogenic bladder</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Optimal dose of RATG remains to be determined. Whether other depleting agents are as effective as RATG is unclear.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Allan D. Kirk</name_or_title>
      <organization>National Institutes of Health</organization>
      <email>allank@intra.niddk.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

